Skip to main content
. Author manuscript; available in PMC: 2013 Jun 15.
Published in final edited form as: Cancer Res. 2012 Apr 17;72(12):3048–3059. doi: 10.1158/0008-5472.CAN-11-3649

Figure 5. BRAFV600E- driven tumors regress upon treatment with MEK inhibitor PD0325901.

Figure 5

Luciferase imaging of BRafCA/+ and BRaf+/+ Luciferase reporter mice following infection with 107 pfu Ad-Cre. Mice were administered 12.5 mg/kg PD32901 at nine weeks post infection and dosed five days a week for five weeks. Bioluminescent signal was measured in photons/second (p/s).